Compounding Pharmacy vs Research Peptide: 7 Key Differences in Sourcing, Quality, Cost & How to Reduce Risk

Three statutory prongs decide everything. A bulk substance qualifies for pharmacy compounding through a USP monograph, through being a component of an approved drug, or through FDA's 503A bulks list. Most peptides reach none of them.

That test, at 21 U.S.C. § 353a(b)(1)(A), is the whole difference between a prescription a pharmacist can fill and a vial that arrives labelled for laboratory use. The dated record behind it is in the FDA peptide regulation timeline, and the position by jurisdiction in are peptides legal.

What is the difference between a compounded peptide and a research vial?

A compounded peptide is a prescription medicine prepared by a licensed pharmacist for a named patient from a bulk substance that satisfies one of three statutory prongs. A research vial is a product sold to anyone with a payment method, from an unspecified source, with no prescription, no statutory certificate on the raw material and no compendial sterility standard. The molecule may be identical. Everything documented about it is not.

The comparison is worth making concretely rather than in the abstract, because for a handful of compounds both routes genuinely exist. Sermorelin is the clearest case: a compound a pharmacy can lawfully compound and a compound FDA has issued a warning letter about when sold as a research chemical. The same molecule, two channels, and one document trail that is entirely absent from the second.

What do the three statutory prongs actually require?

A bulk drug substance used in 503A compounding must do one of three things under 21 U.S.C. § 353a(b)(1)(A): comply with an applicable USP or NF monograph, be a component of an FDA-approved drug, or appear on FDA's 503A bulks list. Any one of the three qualifies it independently. The bulks list itself holds six substances, none of them a peptide, which means in practice that the first two prongs carry all the traffic.

Each prong asks a different question. A monograph means a compendial standard exists defining identity, strength, quality and purity for the substance — an objective specification a pharmacist can test against. A component of an approved drug means the substance is already in something FDA reviewed and approved, so the agency has evaluated it in a manufactured product. The bulks list is the route for substances that satisfy neither and have been nominated, evaluated and affirmatively added, which has happened six times and never for a peptide.

Satisfying a prong is a statutory pathway, not an efficacy endorsement. Gonadorelin qualifies while the published evidence for what it is prescribed for in practice is thin to absent; that combination is entirely possible, because the statute asks about the substance's compendial and regulatory pedigree rather than about whether the use works.

One route runs on a different mechanism entirely and is worth separating out. Compounding a drug that is essentially a copy of an approved product is permitted only while that product is in shortage, which is how compounded semaglutide and tirzepatide were supplied. That route closed when FDA's shortage database moved both to "Resolved," and it never touched the bulks-list machinery at all.

Which compounds satisfy which prong, and which satisfy none?

Four compounds in this corpus reach a prong and the rest do not. Gonadorelin qualifies through USP monographs that exist for the acetate, the hydrochloride and gonadorelin for injection. Oxytocin qualifies through both a monograph and component status. Tesamorelin and sermorelin qualify as components of FDA-approved drugs. BPC-157, TB-500, MOTS-c, semax, epitalon, ipamorelin, CJC-1295, melanotan II and most of the rest satisfy none of the three.

The sermorelin caveat belongs in the open. Both Geref approvals were formally withdrawn in 2009, and we found no FDA document expressly resolving whether a withdrawn approval still satisfies the component prong. FDA's own 503B documentation lists "Sermorelin Acetate" with a component-of-approved-drugs footnote, which implies the agency's answer. The final inferential step is not spelled out in any FDA statement we could locate, and it should not be presented as though it were.

Note also what the last two rows establish. Being absent from FDA's compounding tables is not permission. VIP, aviptadil, FOXO4-DRI and glutathione appear on neither the active Category 2 list nor the withdrawn-nomination table because nobody ever nominated them, so the agency has never looked. A compound nobody asked about is in exactly the same compounding position as one FDA examined and flagged: not compoundable.

How do the two routes compare, requirement by requirement?

The compounded route carries seven documented obligations the research channel carries none of. A valid prescription for a named patient, a licensed pharmacist in a state-licensed pharmacy, active pharmaceutical ingredient from an FDA-registered establishment, a valid certificate of analysis on the bulk substance, USP <795> and <797> sterility and beyond-use dating, documented stability, and for 503B facilities CGMP. A research vial substitutes a disclaimer for all seven.

Read the last row before the others, because the comparison is not between a regulated product and an unregulated one. The compounded route buys a chain of custody, a prescriber and a statutory paperwork standard. It does not buy an approval. That is a real difference and a bounded one, and pages that sell compounding as equivalent to a manufactured drug are overstating it in the opposite direction from the pages that call it "the same as research grade."

The beyond-use dating row is the one with the most practical bite. USP <795> and <797> require a documented in-use period supported by stability data. On the research side, no published stability study exists for most of these compounds, which means the in-use period a vendor prints is a guess unless it traces to an approved label. The mechanics of that, including the one approved label in this corpus that supplies a sourced in-use figure, are in the bacteriostatic water guide.

What does a 503B outsourcing facility add that a 503A pharmacy does not?

Current good manufacturing practice. 503B outsourcing facilities are subject to CGMP; 503A pharmacies are not. That single line is the reason "compounded" is not one standard but two, and it is routinely elided in marketing that uses the word without the section number. A 503A pharmacy compounds for identified individual patients under USP <795> and <797>; a 503B facility may produce larger batches without patient-specific prescriptions, and carries the manufacturing obligations that go with that.

For a buyer, the practical significance is what gets tested and how systematically. CGMP brings process validation, batch records and release testing as an ongoing obligation rather than as an occasional purchase. The tests that matter most on an injectable — sterility under USP <71> and endotoxin by LAL assay — sit inside that regime at 503B, are compendially required at 503A, and are rarely performed at all on research-market material.

The gap is not theoretical. FDA classified a Class I recall of a GenoGenix NAD+ injection for endotoxin contamination on 21 October 2025 — Class I being the most serious category, reserved for products where use may cause serious adverse health consequences or death. Endotoxin survives sterilisation, so filtering out bacteria removes the organisms and leaves the residue behind.

Does a compounded drug carry an FDA approval?

No, and FDA says so in terms that leave no room for interpretation: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." That statement applies to the lawful route, not to the grey market. A compounded sermorelin prescription filled correctly by a licensed pharmacy from qualifying bulk substance still carries no agency review of whether it works or whether that batch is what it says.

This is the sentence most often left out of clinic marketing, and it changes what a prescription actually represents. What the compounded route establishes is that a prescriber assessed a patient, that a licensed professional prepared the medicine to compendial standards, and that the raw material came from a registered source with a certificate attached. What it does not establish is that FDA looked at the finished product, because by design the agency does not.

The same logic runs in the other direction on the compounds that do hold approvals. An approved drug's review covers a specific indication and population — tesamorelin's covers excess abdominal fat in HIV lipodystrophy, not visceral fat generally — so "there is an approved version" is a narrower statement than it usually gets used as.

Does "research use only" labelling protect a seller?

It has been tested on a named peptide and it failed. FDA issued a warning letter to Xcel Research LLC on 10 December 2024 naming seven products including sermorelin. Despite labelling that read "FOR RESEARCH USE ONLY" and "NOT INTENDED FOR HUMAN USE," the agency held the products were unapproved new drugs in violation of sections 505(a) and 301(d) of the Food, Drug and Cosmetic Act, because website evidence established human intended use.

The reasoning is what makes it generalisable. Intended use is established by evidence about how a product is presented and sold, not by the words printed on the vial. A disclaimer sitting alongside dosing guidance, human testimonials or before-and-after imagery does not describe the transaction it accompanies. FDA's broader statement makes the same point about the whole channel: the agency "has warned companies that have illegally sold unapproved drugs... falsely labeled 'for research purposes' or 'not for human consumption.' These products have been sold directly to consumers for human use."

Sermorelin is the compound FDA chose to demonstrate that with, which is why it appears throughout this page. It is also the compound where the contrast is sharpest, because the lawful route genuinely exists alongside the enforced-against one.

This page describes what the documents say about sellers. It does not address any purchaser's position in any jurisdiction, and nothing here is legal advice. For anything touching your own circumstances, the useful source is a qualified professional, not an article.

What does a research vial's certificate establish, and what does it not?

Less than the statutory document it is mistaken for. The certificate the statute requires attaches to the bulk substance and comes from an FDA-registered establishment. What a research vendor publishes is a certificate on a finished vial, usually reporting HPLC purity alone — a measure of homogeneity, not of identity, quantity, sterility or pyrogen load. The two documents share a name and almost nothing else, and the substitution is the single most common misunderstanding in this market.

Three specific blind spots follow from that, and each has a documented failure behind it. Purity does not establish identity: bremelanotide and melanotan II sit about one dalton apart on 1,025, below what HPLC or nominal-mass mass spectrometry resolves. Purity does not establish quantity: this platform records a sermorelin product measuring 12.88 mg against a 10 mg label, a 28.8% overage. Purity does not establish salt form, and FDA's position is that salt forms "are different active ingredients than are used in the approved drugs."

How to read the document you actually have is covered in how to read peptide lab test results, and the specific patterns worth distrusting in red flags in peptide certificates of analysis.

Which claims about compounded peptides survive the record?

Three of nine. Compounding is a genuine legal route for a small number of peptides, 503B facilities really are held to CGMP, and the statutory obligations really are more demanding than anything on the research side. What does not survive is the claim that compounded means FDA-approved, that "pharmaceutical grade" is a regulatory category, that any peptide can be compounded on request, or that a research disclaimer changes a seller's position.

How do you verify which route a supplier is actually on?

Ask which prong, then ask for the bulk-substance certificate. A supplier operating lawfully can name the statutory basis for the substance it is compounding and can produce a certificate on the raw material from an FDA-registered establishment. A supplier that answers with a purity percentage on a finished vial, a "pharmaceutical grade" claim or a research disclaimer has answered a different question, and the substitution is diagnostic rather than incidental.

What does the platform data show on the compounds with both routes?

Two readable patterns, in opposite directions. The Purity Index records sermorelin at 99.34 across 208 recency-weighted tests from 17 laboratories (verified August 2026) against a platform composite of 99.50, while sermorelin price data shows 45 shops in stock, a median of $7.00/mg and a lowest tracked price of $1.00/mg on a 10 mg vial (verified August 2026) — a 15× spread at nominally comparable purity.

A dollar-a-milligram outlier deserves scepticism rather than enthusiasm, particularly given that the sermorelin compound page records one vendor's product measuring 12.88 mg against a 10 mg label, a 28.8% overage. Overfill is not generosity; it is evidence that fill accuracy is not controlled. Endotoxin data is largely absent across sermorelin listings, which on an injectable is the field that matters most and the one most often blank.

Gonadorelin shows the mirror image, and it is the more interesting of the two. Its dataset is one of the thinnest on the platform — 99.48% average purity across just seven independent HPLC tests run between April 2025 and May 2026 from Ethos Analytics, Freedom Diagnostics, Vanguard, Bioviridian and Janoshik, against 219 verified vendors (verified August 2026), with one of those seven recording a product labelled 5 mg testing at 2.12 mg, a 57.6% shortfall. Gonadorelin price data shows just 3 shops in stock, a median of $8.00/mg and a lowest of $6.40/mg on a 10 mg vial (verified 8 August 2026). Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.

Three shops in stock against 219 known vendors, on the one compound here with the cleanest compounding pathway, is a pattern worth reading rather than passing over. It is consistent with most legitimate demand flowing through prescriptions and compounding pharmacies rather than research vials — which, for once, is the healthier structure. Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026), weighting community reviews and independently verified purity equally at 50% each, with individual results in the lab test database.

The trial that would settle this

Nobody has compared compounded and research-market material analytically, and the design is straightforward. The claim that the two routes deliver the same product is made constantly and has never been tested on identity, net content, endotoxin or sterility. Sermorelin, gonadorelin, oxytocin and tesamorelin are the four compounds where both channels exist simultaneously, which makes them the natural comparison set and the only one available.

Frequently Asked Questions

Can a compounding pharmacy make BPC-157 for me?

Not lawfully. BPC-157 has no USP monograph, is not a component of any FDA-approved drug and does not appear on FDA's 503A bulks list, so it satisfies none of the three statutory prongs. An advisory committee recommended it 8–6 with one abstention in July 2026 over the written objection of FDA's own reviewers, but that vote is non-binding, no rulemaking has begun and nothing has been added to any list.

Is a compounded peptide FDA-approved?

No. FDA states it plainly: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." The compounded route establishes a prescriber, a licensed preparer, a registered API source and a compendial standard. It does not establish that the agency reviewed the finished product, because by design it does not review it.

What is the difference between 503A and 503B?

A 503A pharmacy compounds for identified individual patients under a prescription and works to USP <795> and <797>. A 503B outsourcing facility may produce larger batches without patient-specific prescriptions and is additionally subject to CGMP, which 503A pharmacies are not. "Compounded" without a section number therefore describes two materially different regimes, and the word alone does not tell a buyer which one applies.

Does "research use only" on the label make a vial legal?

FDA has held that it does not. In a warning letter dated 10 December 2024 to Xcel Research LLC, naming seven products including sermorelin, the agency held that despite labelling reading "FOR RESEARCH USE ONLY" and "NOT INTENDED FOR HUMAN USE," the products were unapproved new drugs under sections 505(a) and 301(d), because website evidence established human intended use. Intended use is inferred from how a product is presented and sold.

Why can gonadorelin be compounded when ipamorelin cannot?

Because gonadorelin reaches the first prong and ipamorelin reaches none. USP monographs exist for gonadorelin acetate, gonadorelin hydrochloride and gonadorelin for injection, and complying with an applicable monograph independently qualifies a bulk substance under 21 U.S.C. § 353a(b)(1)(A)(i). Ipamorelin has no monograph, is not a component of an approved drug and sits on FDA's active Category 2 list, added 29 September 2023.

Is "pharmaceutical grade" a real standard?

Not one this record can locate a definition for. It has no statutory or compendial meaning in the documents behind this page, unlike USP <795>, USP <797>, CGMP and the § 353a prongs, which all have specific content. Treat it as marketing language and ask instead which prong applies, which section the preparer operates under, and which certificate is being shown.

Where this leaves the comparison

The two routes are not two grades of the same thing. One is a prescription medicine prepared under a statute that specifies who may receive it, who may prepare it, where the raw material comes from and what documentation must exist. The other is a product sold openly with a disclaimer, and the disclaimer has been tested by FDA on a named peptide and did not hold.

What the compounded route does not do is worth stating as plainly as what it does. It carries no FDA approval, 503A pharmacies are not held to CGMP, and for most peptides the route does not exist at all because the substance reaches none of the three prongs. The honest summary is that a small number of compounds have a real legal channel, that channel is meaningfully more documented than the alternative, and it still stops well short of an approved drug.

Browse the growth hormone peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the peptide dosing calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.